India, Oct. 23 -- AbbVie (ABBV) announced that the U.S. Food and Drug Administration approved a subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease, providing patients with a new option to begin treatment at home.
The approval is supported by positive results from the Phase 3 AFFIRM trial, which evaluated the efficacy and safety of subcutaneous SKYRIZI versus placebo in patients with moderately to severely active Crohn's disease. The study met its co-primary endpoints, with SKYRIZI demonstrating superiority in achieving both clinical remission and endoscopic response at Week 12.
With the newly approved subcutaneous induction regimen, patients can start SKYRIZI treatm...